الرئيسية › سرطان الثدي الثلاثي السلبي › تكساس › Houston
التجارب السريرية لـ سرطان الثدي الثلاثي السلبي في Houston، TX
42 دراسات لـ سرطان الثدي الثلاثي السلبي تبحث عن مشاركين في مواقع داخل وحول Houston (ضمن نطاق 30 ميلًا تقريبًا). افتح الدراسة لمعرفة من يمكنه المشاركة وكيفية التواصل مع فريق الدراسة.
النص الرسمي للدراسة (بالإنجليزية)
تبحث عن مشاركين لدراسة؟ أبرزها في أعلى الصفحة — $99 لمدة 30 يومًا →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
جارٍ التسجيلالمرحلة 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
جارٍ التسجيلالمرحلة 1
- University of Texas MD Anderson Cancer Center, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- MD Anderson Cancer Center, Houston
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
جارٍ التسجيلالمرحلة 1/2
- MD Anderson Cancer Center, Houston
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
جارٍ التسجيل
- M D Anderson Cancer Center, Houston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
جارٍ التسجيلالمرحلة 3
- Kelsey-Seybold Clinic ( Site 0042), Houston
- Kelsey-Seybold Clinic ( Site 0088), Houston
- Oncology Consultants P.A. ( Site 0073), Houston
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
جارٍ التسجيلالمرحلة 3
- Oncology Consultants P.A. ( Site 0107), Houston
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
جارٍ التسجيلالمرحلة 3
- Kelsey-Seybold Clinic - North Houston Campus ( Site 0096), Houston
- Kelsey-Seybold Clinic ( Site 0040), Houston
Intratumoral N17350 in Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
جارٍ التسجيلالمرحلة 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
جارٍ التسجيلالمرحلة 2
- Baylor College of Medicine, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
جارٍ التسجيلالمرحلة 1
- MD Anderson Cancer Center, Houston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
جارٍ التسجيلالمرحلة 3
- MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- The University of Texas - MD Anderson Cancer Center, Houston
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
جارٍ التسجيلدراسة رصدية
- UT Health Houston, Houston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Research Site, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
جارٍ التسجيلالمرحلة 1
- Normunity Investigational Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- Houston Methodist Hospital, Houston
SMP-3124LP in Adults With Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- MD Anderson Cancer Center, Houston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
جارٍ التسجيلالمرحلة 2/3
- (USOR) Texas Oncology, Houston
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
جارٍ التسجيلالمرحلة 1
- UT MD Anderson Cancer Center, Houston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
جارٍ التسجيلالمرحلة 1
- Uni Of TX MD Anderson Cancer Cntr, Houston
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
جارٍ التسجيلالمرحلة 1
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
جارٍ التسجيلالمرحلة 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
جارٍ التسجيلالمرحلة 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
جارٍ التسجيلالمرحلة 1/2
- MD Anderson, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
جارٍ التسجيلالمرحلة 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
A Study of LY4175408 in Participants With Advanced Cancer
جارٍ التسجيلالمرحلة 1
- MD Anderson Cancer Center, Houston
Study of XB010 in Subjects With Solid Tumors
جارٍ التسجيلالمرحلة 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
جارٍ التسجيلالمرحلة 1
- MD Anderson, Houston
- NEXT Texas LLC - Houston, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
جارٍ التسجيلالمرحلة 1
- The University of Texas MD Anderson Cancer Center, Houston
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
جارٍ التسجيلالمرحلة 2
- Houston Methodist Neal Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
جارٍ التسجيلالمرحلة 2
- MD Anderson Cancer Center, Houston
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
جارٍ التسجيلالمرحلة 1
- MD Anderson Cancer Center, Houston
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
جارٍ التسجيلالمرحلة 1/2
- M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
جارٍ التسجيلالمرحلة 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
جارٍ التسجيلالمرحلة 1
- MD Anderson Cancer Center, Houston
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
جارٍ التسجيلالمرحلة 2
- Harris Health System - Smith Clinic, Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston
CtDNA Based MRD Testing for NAC Monitoring in TNBC
جارٍ التسجيلدراسة رصدية
- The University of Texas MD Anderson Cancer Center, Houston
تجارب سرطان الثدي الثلاثي السلبي في مدن أخرى
- New York City, NY31 دراسات
- Nashville, TN28 دراسات
- Los Angeles, CA27 دراسات
- Boston, MA26 دراسات
- San Antonio, TX23 دراسات
- St. Louis, MO21 دراسات
- Atlanta, GA20 دراسات
- Arlington, VA20 دراسات
- Dallas, TX18 دراسات
- Chicago, IL16 دراسات
- Columbus, OH16 دراسات
- Tampa, FL15 دراسات
دراسات أخرى في Houston
- سرطان الرئة غير صغير الخلايا145 دراسات
- سرطان الثدي126 دراسات
- السرطان (جميع الأنواع)121 دراسات
- السرطان النقيلي104 دراسات
- سرطان القولون والمستقيم102 دراسات
- سرطان المبيض89 دراسات
- ابيضاض الدم النقوي الحاد85 دراسات
- سرطان الرئة78 دراسات
- سرطان البروستاتا76 دراسات
- سرطان بطانة الرحم68 دراسات
- سرطان البنكرياس61 دراسات
- ميلانوما59 دراسات
من ClinicalTrials.gov، البيانات مستخرجة في 05/10/2026. كل دراسة تحدد معايير أهليتها الخاصة؛ فريق الدراسة هو من يحدد من يمكنه المشاركة.